Larimar Therapeutics (LRMR)

• Market cap: $289M
• 1 day: -2.8%
• 5 days: -11.18%
• 1 month: -31.86%
• 3 months: -15.5%
• 6 months: -44.95%
• Year to date: -19.88%
• 1 year: -42.2%
• 5 years: -73.55%
• 10 years: -93.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Employees: 71